The flurry of business development activity at Aptar continues. Having made moves for injectable drug delivery and digital therapeutic players in recent weeks, Aptar has now nabbed (PDF) an option on ...
Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...
3M ($MMM) licensed its dry powder drug delivery device for asthma and chronic obstructive pulmonary disease (COPD) to Adamis for an undisclosed amount, granting the ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive ...
The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...
The divided solid materials have a significant share in the products produced or employed in the pharmaceutical industries (such as active pharmaceutical ingredient (API), excipients, additives, and ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback